Alnylam Broadens Pipeline with ALN-AGT, a Subcutaneously Administered RNAi Therapeutic Targeting Angiotensinogen (AGT) for the Treatment of Hypertensive Disorders of Pregnancy (HDP), Including Preeclampsia